The2X-121, a small molecular targeting the PARP, as well as the tankyrases (TNKS1 and TNKS2), showed anti-tumor activity in patients with various types of solid tumor and are generally well tolerated in Phase 1 trial (NCT01618136) (47). Here, TNKS is linked to neoplasm.